<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Zaman, S on BayesRx</title>
    <link>https://bayesrx.github.io/authors/zaman-s/</link>
    <description>Recent content in Zaman, S on BayesRx</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Thu, 23 Mar 2017 00:00:00 -0400</lastBuildDate>
    
	<atom:link href="https://bayesrx.github.io/authors/zaman-s/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma</title>
      <link>https://bayesrx.github.io/publication/phase2cmet/</link>
      <pubDate>Thu, 23 Mar 2017 00:00:00 -0400</pubDate>
      
      <guid>https://bayesrx.github.io/publication/phase2cmet/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>